Physician profile
Barbara Bierer
NPI 1285642298
$28,247.98
in general payments reported to CMS, 2019-2025
4 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $9,975 · 2023: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Food and Beverage: $45.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,227.36 |
| Food and Beverage | $45.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi US Services INC. | $12,429.18 | 2023 | |
| Eli Lilly and Company | $8,575.00 | 2021 | |
| Merck Sharp & Dohme LLC | $5,843.80 | 2023 | Gardasil 9 |
| Gilead Sciences, INC. | $1,400.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Bierer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.